

6. Literaturverzeichnis:

1. van den Aardweg GJ, Naus NC, Verhoeven AC, de Klein A, Luyten GP: Cellular radiosensitivity of primary and metastatic human uveal melanoma cell lines. *Invest Ophthalmol Vis Sci* 2002;43:2561-2565.
2. Agosteo S, Birattari C, Caravaggio M, Silari M, Tosi G: Secondary neutron and photon dose in proton therapy. *Radiother Oncol* 1998;48:293-305.
3. Astrahan NA, Luxton G, Pu Q, Petrovich Z: Conformal episcleral plaque radiotherapy. *Int J Radiat Oncol Biol Phys* 1997;39:505-515
4. Augsburger JJ, Schneider S, Freire J, Brady LW: Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroidal melanomas: Results in patients treated 1980 and 1987. *Graefes Arch Clin Exp Ophthalmol* 1999;237:558-567.
5. Baumert BG, Lomax AJ, Miltchev V, Davis JB: A comparison of dose distributions of proton and photon beams in stereotactic conformal radiotherapy of brain lesions. *Int J Radiat Oncol Biol Phys* 2001;49:1439-1449.
6. Bechrakis NE, Bornfeld N, Zöller I, Foerster MH: Iodine 125 plaque brachytherapy versus transscleral resection in the treatment of large uveal melanomas. *Ophthalmology* 2002b;109:1855-1861.
7. Bechrakis NE, Foerster MH: Where is the superiority of proton radiation for ocular tumors? *Graefe's Arch Clin Exp Ophthalmol* 2002;240:513-514.
8. Bechrakis NE, Foerster MH, Bornfeld N: Biopsy in indeterminate intraocular tumors. *Ophthalmology* 2002a;109:235-242.
9. Bogner J, Petersch B, Georg D, Dieckmann K, Zehetmayer M, Pötter R: A noninvasive eye fixation and computer-aided eye monitoring system for linear accelerator-based stereotactic radiotherapy of uveal melanoma. *Int J Radiat Oncol Biol Phys* 2003;56:1128-1136.
10. Bornfeld N, Chauvel P, Sauerwein W, Friedrichs W, Tiburtius T, Wessing A, Foerster MH: Metastatic disease, eye retention and visual function in conservative treatment of uveal melanoma. In: Wiegel T, Bornfeld N, Foerster MH, Hinkelbein W (Hrsg.): Radiotherapy of ocular disease. *Front Radiat Ther Oncol* 1997;30:97-110.

11. Bush DA, McAllister CJ, Loredo LN, Johnson WD, Slater JM, Slater JD: Fractionated proton beam radiotherapy for acoustic neuroma. *Neurosurgery* 2002;50:270-275.
12. Castro JR, Char DH, Petti PL, Daftari IK, Quivey JM, Singh RP, Blakely EA, Phillips TL: 15 years experience with helium ion radiotherapy for uveal melanoma. *Int J Radiat Oncol Biol Phys* 1997;39:989-996.
13. Celli L, Lomax A, Miralbell R: Potential role of intensity modulated proton beams in prostate cancer radiotherapy. *Int J Radiat Oncol Biol Phys* 2001;49:217-223.
14. Chabert S, Velikay-Parel M, Zehetmayer M: Influence of uveal melanoma therapy on patients' quality of life: a psychological study. *Acta Ophthalmol Scand* 2004;82:25-31.
15. Char DH, Miller T, Crawford JB: Uveal tumor resection. *Br J Ophthalmol* 2001;85:1213-1219.
16. Char DH, Kroll SM, Castro J: Ten-year follow-up of helium ion therapy for uveal melanoma. *Am J Ophthalmol* 1998;125:81-89.
17. Char DH, Kroll SM, Phillips TL: Uveal melanoma. Growth rate and prognosis. *Arch Ophthalmol* 1997;115:1014-1018.
18. Chauvel P, Sauerwein W, Bornfeld N, Friedrichs W, Brassart N, Courdi A, Herault J, Pignol JP, Bondiau PY, Malandain G and the participants of the SERAG: Clinical and technical requirements for proton treatment planning of ocular diseases. In: Wiegel T, Bornfeld N, Foerster MH, Hinkelbein W (Hrsg.): Radiotherapy of ocular disease. *Front Radiat Ther Oncol* 1997; 30:133-142.
19. Chiquet C, Grange JD, Ayzac, Chauvel P, Patricot LM, Devouassoux-Shisheboran M: Effects of proton beam irradiation on uveal melanomas: A comparative study of Ki-67 expression in irradiated versus non-irradiated melanomas. *Br J Ophthalmol* 2000;84:98-102.
20. Cogan DG, Donaldson DD, Reese AB: Clinical and pathological characteristics of radiation cataract. *Ama Arch Ophthalmol* 1952;47:55-70.
21. Cohen VM, Carter MJ, Kemeny A, Radatz M, Rennie IG: Metastasis-free survival following treatment for uveal melanoma with either stereotactic radiosurgery or enucleation. *Acta Ophthalmol Scand* 2003;81:383-388.

22. Collaborative Ocular Melanoma Study Group. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol 1998;125:745-766.
23. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma II. Initial mortality findings. COMS report no. 10. Am J Ophthalmol 1998;125:779-796.
24. Colombo F, Benedetti A, Pozza F, Avanzo RC, Marchetti C, Chierego G, Zanardo A: External stereotactic irradiation by linear accelerator. Neurosurgery 1985;16:154-160.
25. Courdi A, Caujolle JP, Grange JD, Diallo-Rosier L, Sahel J, Bacin F, Zur C, Gastaud P, Iborra-Brassart N, Herault J, Chauvel P: Results of proton therapy of uveal melanomas treated in Nice. Int J Radiat Oncol Biol Phys 1999;45:5-11.
26. Cozzi L, Fogliati A, Lomax A, Bolsi A: A treatment planning comparison of 3 D conformal therapy, intensity modulated photon therapy and proton therapy for treatment of advanced head and neck tumors. Radiother Oncol 2001;61:287-297.
27. Daftari IK, Char DH, Verhey LJ, Castro JR, Petti PL, Meecham WJ, Kroll S, Blakely EA: Anterior segment sparing to reduced charged particle radiotherapy complications in uveal melanoma. Int J Radiat Oncol Biol Phys 1997;39:997-1010.
28. Damato BE, Paul J, Foulds WS: Risk factors for metastatic uveal melanoma after trans-scleral local resection. Br J Ophthalmol 1996;80:102-108.
29. Desjardins L, Lumbroso L, Levy C, Mazal A, Delacroix S, Rosenwald JC, Dendale R, Plancher C, Asselain B: Traitement du mélanome choroidien par disque d'iode et faisceau de protons: Indications respectives et comparaison des taux de récidive. J Fr Ophtalmol 2003;26:269-276.
30. Dieckmann K, Bogner J, Georg D, Zehetmayer M, Kren G, Pötter R: A linac-based stereotactic irradiation technique of uveal melanoma. Radiother Oncol 2001;61:49-56.
31. Dieckmann K, Georg D, Zehetmayer M, Bogner J, Georgopoulos M, Pötter R: Linac based stereotactic radiotherapy of uveal melanomas: 4 years clinical experience. Radiother Oncol 2003;67:199-203.

32. Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, Schachat AP, Straatsma BR; Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001;119:969-982.
33. Egan KM, Gragoudas ES, Seddon JM, Glynn RJ, Munzenreider JE, Goitein M, Verhey L, Urie M, Koehler A: The risk of enucleation after proton beam irradiation of uveal melanoma. Ophthalmology 1989;96:1377-1382.
34. Egger E, Schalenbourg A, Zografos L, Bercher L, Boehringer T, Chamot L, Goitein G: Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys 2001;51:138-147.
35. Egger E, Zografos L, Perret C, Gailloud C: Proton Beam Irradiation of choroidal melanomas at PSI: Technique and results. In: Alberti WE, Sagerman RH (Hrsg.): Radiotherapy of intraocular and orbital tumors. Medical radiology. Diagnostic Imaging and radiation oncology; 1993; Springer, Berlin, Heidelberg, New York. S.57-72.
36. Egger E, Zografos L, Schalenbourg A, Böhringer T, Chamot L, Goitein G: Eye retention after proton beam radiotherapy for uveal melanoma: Int J Radiat Oncol Biol Phys 2003;55:867-880.
37. Finger PT: Tumor location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol 2000;84:1068-1070.
38. Finger PT, Lipka A, Lipkowitz J, Jofe M, McCormick SA: Failure of transpupillary thermotherapy (TTT). Br J Ophthalmol 2001;84:1075-1076.
39. Foss AJ, Whelehan I, Hungerford JL, Anderson DF, Errington RD, Kacperek A, Restori M, Kongerud J, Sheen M: Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma. Br J Ophthalmol 1997;81:748-754.
40. Freire JE, Brady LW, Shields JA, Shields CL: Eye and orbit. In: Perez CA, Brady LW, Halperin EC, Schmidt-Ulrich RK (Hrsg.): Principles and practice of radiation oncology; 4. Ausgabe 2004; Lippincott Williams & Wilkins, Philadelphia; S. 876-896.

41. Fuss M, Loredo LN, Blacharski PA, Grove RI, Slater JD: Proton radiation therapy for medium and large choroidal melanoma: preservation of the eye and its functionality. *Int J Radiat Oncol Biol Phys* 2001;49:1053-1059.
42. Fuss M, Poljanc K, Miller DW, Archambeau JO, Slater JM, Slater JD, Hug EB: Normal tissue complication probability (NTCP) calculations as a means to compare proton and photon plans of clinical appropriateness of calculated values. *Int J Cancer (Radiat Oncol Invest)* 2000;90:351-358.
43. Georg D, Dieckmann K, Bogner J, Zehetmayer M, Pötter R: Impact of micromultileaf collimator on stereotactic radiotherapy of uveal melanoma. *Int J Radiat Oncol Biol Phys* 2003;55:881-891.
44. Goitein M, Miller T: Planning proton therapy of the eye. *Med Phys* 1983;10:275-283.
45. Gordon KB, Char DH, Sagerman RH: Late effects of radiation on the eye and ocular adnexa. *Int J Radiat Oncol Biol Phys* 1995;31:1123-1139.
46. Gragoudas E, Goitein M, Koehler AM, Verhey L, Tepper J, Suit HD, Brockhurst R, Constable IJ: Proton irradiation of small choroidal malignant melanomas. *Am J Ophthalmology* 1977;83:666-673.
47. Gragoudas ES, Goitein M, Verhey L, Munzenrider J, Suit HD, Koehler A: Proton beam irradiation—An alternative to enucleation for intraocular melanomas. *Ophthalmology* 1980;87:571-581.
48. Gragoudas ES, Lane AM, Munzenrider J, Egan KM, Li W: Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. *Trans Am Ophthalmol Soc.* 2002a;100:43-8.
49. Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM: Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. *Ophthalmology* 1999;106:1571-1577.
50. Gragoudas ES, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM: Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. *Arch Ophthalmol* 2002b;120:1665-1671.
51. Haas A, Pinter O, Papaefthymiou G, Weger M, Berghold A, Schröttner O, Müllner K, Pendl G, Langmann G: Incidence of radiation retinopathy after high-dosage single-fraction gamma knife radiosurgery for choroidal melanoma. *Ophthalmology* 2002;109:909-913.

52. Ham WT: Radiation cataract. *Ama Arch Ophthalmol* 1953;50:618-643.
53. Heese J, Kluge H, Fuchs H, Homeyer H, Morgenstern H, Rethfeld C, Reng I, Nausner M, Bechrakis NE, Kreusel KM, Bornfeld N, Hinkelbein W, Foerster MH: Proton beam eye treatment in Berlin: Experiences of the first two years. In: International Conference on Ocular Pathologies 2001, Catania, Italy: Physica Media 2001;17 Suppl 3:20-22.
54. Heufelder J, Cordini D, Fuchs H, Heese J, Homeyer H, Kluge H, Morgenstern H, Höcht S, Nausner M, Bechrakis NE, Hinkelbein W, Foerster MH: Fünf Jahre Protonentherapie am Hahn-Meitner-Institut Berlin. *Z Med Phys* 2004, 14; 64-71.
55. Höcht S, Bechrakis NE, Nausner M, Kreusel KM, Kluge H, Heese J, Heufelder J, Cordini C, Fuchs H, Martus P, Foerster MH, Hinkelbein W: Proton therapy of uveal melanomas in Berlin. 5 years of experience at the Hahn-Meitner-Institut. *Strahlenther Onkol* 2004; im Druck
56. Hosten N, Bornfeld N, Wassmuth R, Lemke AJ, Sander B, Bechrakis NE, Felix R: Uveal melanoma: Detection of extraocular growth with MR imaging and US. *Radiology* 1997;204:874-875
57. Hsiung-Stripp DC, McDonough J, Masters HM, Levin WP, Hahn SM, Jones HA, Metz JM: Comparative treatment planning between proton and x-ray therapy in pancreatic cancer. *Med Dosim* 2001;3:255-259.
58. Hug EB, Adams J, Fitzek M, De Vries A, Munzenrider JE: Fractionated, three-dimensional, planning-assisted proton-radiation therapy for orbital rhabdomyosarcoma: A novel technique. *Int J Radiat Oncol Biol Phys* 2000;47:979-984.
59. Hug EB, Muenter MW, Adams JA, de Vries A, Rosenberg AE, Munzenrider JE: 3-D-conformal radiation therapy for pediatric giant cell tumors of the skull base. *Strahlenther Onkol* 2002a;178:239-244.
60. Hug EB, Muenter MW, Archambeau JO, DeVries A, Liwnicz B, Loredo LN, Grove RI, Slater JD: Conformal proton radiation therapy for pediatric low-grade astrocytomas *Strahlenther Onkol* 2002b;178:10-17.
61. Jones B, Errington RD: Proton beam radiotherapy. *Br J Radiol* 2000;73: 802-805.

62. Jones B, Dale RG: Estimation of optimum dose per fraction for high LET radiations: Implications for proton radiotherapy. *Int J Radiat Oncol Biol Phys* 2000;48:1549-1557.
63. Karvat A, Duzenli C, Ma R, Paton K, Pickles T: The treatment of choroidal melanoma with ^{198}Au plaque brachytherapy. *Radiother Oncol* 2000;59:153-156.
64. Kunz H, Derz C, Tolxdorff T, Bernarding J: Feature extraction and supervised classification of MR images to support proton radiation therapy of eye tumors. *Comput Methods Programs Biomed* 2004;73:195-202.
65. Langmann G, Pendl G, Müllner K, Papaefthymiou G, Guss H: Gamma knife radiosurgery for uveal melanomas: An 8-year experience. *J Neurosurg* 2000;93 Suppl. 3:184-188.
66. Lemke AJ, Hosten N, Bornfeld N, Bechrakis NE, Schuler A, Richter M, Stroszczynski C, Felix R: Uveal melanoma: Correlation of histopathologic and radiologic findings by using thin-section MR imaging with a surface coil. *Radiology* 1999;210:775-783.
67. Levitt SH: Secondary malignancies after radiotherapy. In: Dunst J, Sauer R: (Hrsg.) Late Sequelae in Oncology. Medical radiology. Diagnostic Imaging and radiation oncology; 1995; Springer, Berlin, Heidelberg, New York. S.279-289.
68. Li W, Gragoudas ES, Egan KM: Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma. *Arch Ophthalmol* 2000;118:1066-70.
69. Li W, Gragoudas ES, Egan KM: Tumor basal area and metastatic death after proton beam irradiation for choroidal melanoma: *Arch Ophthalmol* 2003;121:68-72.
70. Lin R, Hug EB, Schaefer RA, Miller DW, Slater JM, Slater JD: Conformal proton radiation therapy of the posterior fossa: A study comparing protons with three dimensional planned photons in limiting dose to auditory structures. *Int J Radiat Oncol Biol Phys* 2000;48:1219-1226.
71. Lindqvist M, Steiner L, Blomgren H, Arndt J, Berggren B: Stereotactic radiation therapy of intracranial arteriovenous malformations. *Acta Radiol Suppl.* 1986;69:610-613.

72. Lommatsch PK, Vollmar R: Ein neuer Weg zur konservativen Therapie intraokularer Tumoren mit Betastrahlen (Ru-106/Rh-106) unter Erhaltung der Sehfähigkeit. Klin Monatsbl. Augenheilkd. 1966;148:682-699.
73. Lommatsch PK, Werschnik C, Schuster E: Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma. Graefe's Arch Clin Exp Ophthalmol 2000;238:129-137.
74. Lomax A: Intensity modulation methods for proton radiotherapy. Med Phys Biol 1999;44:185-205.
75. Lomax AJ, Bortfeld T, Goitein G, Debus J, Dykstra C, Tercier AP, Coucke PA, Mirimanoff RO: A treatment planning inter-comparison of proton and intensity modulated photon radiotherapy. Radiother Oncol 1999;51:257-271
76. Lomax AJ, Goitein M, Adams J: Intensity modulation in radiotherapy: photons versus protons in the paranasal sinus. Radiother Oncol 2003;66:11-18.
77. Lumbroso L, Desjardins L, Levy C, Plancher C, Frau E, D'Hermies F, Schlienger P, Mammar H, Delacroix S, Nauraye C, Ferrand R, Desblancs C, Mazal A, Asselain B: Intraocular inflammation after proton beam irradiation for uveal melanoma. Br J Ophthalmol 2001;85:1305-1308.
78. Marchini G, Gerosa M, Piovan E, Pasoli A, Babighian S, Rigotti M, Rossato M, Bonomi L: Gamma knife stereotactic radiosurgery for uveal melanoma: Clinical results after 2 years. Stereotact Funct Neurosurg 1996;66:208-213.
79. Meecham WJ, Char DH, Kroll S, Castro JR, Blakely EA: Anterior segment complication after helium ion radiation therapy for uveal melanoma. Arch Ophthalmol 1994;112:197-203.
80. Meredith TA. Choroidal melanoma: Diagnosis and management. Am J Ophthalmol 1998;125:865-867.
81. Merriam GR, Focht EF: A clinical and experimental study of the effect of single and divided doses of radiation on cataract production. Trans Am Ophthalmol Soc. 1962;60:35-52.
82. Miralbell R, Celli L, Weber D, Lomax A: Optimizing radiotherapy of orbital and paraorbital tumors: Intensity-modulated x-ray beams vs. intensity-modulated proton beams. Int J Radiat Oncol Biol Phys 2000;47:1111-1119.

83. Miralbell R, Lomax A, Cella L, Schneider U: Potential Reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. *Int J Radiat Oncol Biol Phys* 2002;54:824-829.
84. Mock U, Georg D, Bogner J, Auberger T, Pötter R: Treatment planning comparison of conventional, 3D conformal , and intensity modulated photon (IMRT) and proton therapy for paranasal sinus carcinoma. *Int J Radiat Oncol Biol Phys* 2004;58:147-154.
85. Mueller AJ, Talies S, Schaller UC , Horstmann G, Wowra B, Kampik A: Stereotactic radiosurgery of large uveal melanomas with the gamma-knife. *Ophthalmology* 2000;107:1381-1387.
86. Muller K, Nowak PJ, Luyten GP, Marijnissen JP, de Pan C, Levendag P: A modified relocatable stereotactic frame for irradiation of eye melanoma: Design and evaluation of treatment accuracy. *Int J Radiat Oncol Biol Phys* 2004; 58:284-291.
87. Munzenrider J: Proton therapy for uveal melanomas and other eye lesions. *Strahlenther Onkol.* 1999;175 Suppl 2:68-73.
88. Munzenrider JE, Gragoudas ES, Seddon JM, Sisterson J, McNulty P, Birnbaum S, Johnson K, Austin-Seymour M, Slater J, Goitein M, et al.: Conservative treatment of uveal melanoma: Probability of eye retention after proton treatment. *Int J Radiat Oncol Biol Phys* 1988;15:553-558.
89. Nag S, Quivey JM, Earle JD, Followill D, Fontanesi J, Finger PT for the American Brachytherapy Society: The American Brachytherapy Society Recommendations for brachytherapy of uveal melanomas. *Int J Radiat Oncol Biol Phys* 2003;56:544-555.
90. Nguyen LN, Ang KK: The orbit. In: Cox JD, Ang KK (Hrsg.): *Radiation Oncology: Rationale, technique, results*; 8. Ausgabe 2003; Mosby Inc. St. Louis; S.282-292.
91. Noren G, Arndt J, Hindmarsh P: Stereotactic radiosurgery in cases of acoustic neurinoma: further experiences. *Neurosurgery* 1983;13:12-22.
92. Oosterhuis JA, Journee de Korver HG, Kakebeeke-Kemme HM, Bleeker JC: Transpupillary thermo-therapy in choroidal melanomas. *Arch Ophthalmol* 1995;113:315-321.

93. Packer S, Stoller S, Lesser ML, Mandel FS, Finger PT: Long term results of iodine 125 irradiation of uveal melanoma. *Ophthalmology* 1992;99:767-774.
94. Pai HH, Thornton A, Katzenstein L, Finkelstein DM, Adams JA, Fullerton BC, Loeffler JS, Liebsch NJ, Klibanski A, Munzenrider JE: Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of the skull: Demonstration of a dose-effect relationship using dose-volume histogram analysis. *Int J Radiat Oncol Biol Phys* 2001;49:1079-1092.
95. Petrovich Z, Luxton G, Langholz B, Astrahan MA, Liggett PE: Episcleral plaque radiotherapy in the treatment of uveal melanomas. *Int J Radiat Oncol Biol Phys* 1992;24:247-251.
96. Quivey JM, Augsburger J, Snelling L, Brady LW: 125-I plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control. *Cancer* 1996;77:2356-2362.
97. Rennie I, Forster D, Kemeny A, Walton L, Kunkler I: The use of single fraction Leksell stereotactic radiosurgery in the treatment of uveal melanoma. *Acta Ophthalmol Scand* 1996;74:558-562.
98. Saunders WM, Char DH, Quivey JM, Castro JR, Chen GT, Collier JM, Cartigny A, Blakely EA, Lyman JT, Zink SR, et al: Precision, high dose radiotherapy. Helium ion treatment of uveal melanoma. *Int J Radiat Oncol Biol Phys* 1985;11:227-233.
99. Schneider U, Agosteo S, Pedroni E, Besserer J: Secondary neutron dose during proton therapy using spot scanning. *Int J Radiat Oncol Biol Phys* 2002;53:244-251.
100. Seddon JM, Gragoudas ES, Albert DM, Hsieh CC, Polivogianis L, Friedenberg GR: Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation. *Am J Ophthalmol* 1985;99:282-290.
101. Shields CL, Shields JA: Histopathology of uveal malignant melanoma and other uveal tumor. In: Alberti WE, Sagerman RH (Hrsg.): Radiotherapy of intraocular and orbital tumors. Medical radiology. Diagnostic Imaging and radiation oncology; 1993; Springer, Berlin, Heidelberg, New York. S.9-18.
102. Shields CL, Shields JA, Cater J, Gunduz K, Miyamoto C, Micaily B, Brady LW: Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. *Arch Ophthalmol* 2000;118:1219-1228.

103. Simonova G, Novotny J, Liscak R, Pilbauer J: Leksell gamma knife treatment of uveal melanoma. *J Neurosurg* 2002;97 Suppl 5:635-639.
104. Steiner L, Leksell L, Forster DM, Greitz T, Backlund EO: Stereotactic radiosurgery in intracranial arterio-venous malformations. *Acta Neurochir* 1974; Suppl 21:195-209.
105. Straatsma BR, Diener-West M, Caldwell R, Engstrom RE; Collaborative Ocular Melanoma Study Group: Mortality after deferral of treatment or no treatment for choroidal melanoma. *Am J Ophthalmol.* 2003;136:47-54.
106. Sturm V, Kober B, Hover KH, Schlegel W, Boesecke R, Pastyr O, Hartmann GH, Schabbert S, zum Winkel K, Kunze S: Stereotactic percutaneous single dose irradiation of brain metastases with a linear accelerator. *Int J Radiat Oncol Biol Phys.* 1987;13:279-282.
107. Suit HD: Protons to replace photons in external beam radiation therapy? *Clin Oncol (R Coll Radiol)* 2003;15: Suppl 1:29-31.
108. Suit H: The Gray Lecture 2001: Coming technical advances in radiation oncology. *Int J Radiat Oncol Biol Phys* 2002;53:798-809.
109. Tokuyue K, Akine Y, Sumi M, Kagami Y, Ikeda H, Kaneko A: Fractionated stereotactic radiotherapy for choroidal melanoma. *Radiother Oncol* 1997; 43:87-91.
110. Wilson MW, Hungerford JL: Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. *Ophthalmology* 1999;106:1579-1587.
111. Yeboah C: Intensity and energy modulated radiotherapy with proton beams: Variables affecting optimal prostate plan. *Med Phys* 2002;29:176-189.
112. Zagars GK, Ballo MT, Lee AK, Strom SS: Mortality after cure of testicular seminoma: *J Clin Oncol* 2004; 22: 640-647.
113. Zehetmayer M, Kitz K, Menapace R, Ertl A, Heinzl H, Ruhswurm I, Georgopoulos M, Dieckmann K, Pötter R: Local tumor control and morbidity after one to three fractions of stereotactic external beam irradiation for uveal melanoma. *Radiother Oncol* 2000;55:135-144.